ES2421538T3 - Proteasas no pancreáticas para controlar la concentración de colecistocinina (CCK) en plasma y para tratar el dolor - Google Patents

Proteasas no pancreáticas para controlar la concentración de colecistocinina (CCK) en plasma y para tratar el dolor

Info

Publication number
ES2421538T3
ES2421538T3 ES04796860T ES04796860T ES2421538T3 ES 2421538 T3 ES2421538 T3 ES 2421538T3 ES 04796860 T ES04796860 T ES 04796860T ES 04796860 T ES04796860 T ES 04796860T ES 2421538 T3 ES2421538 T3 ES 2421538T3
Authority
ES
Spain
Prior art keywords
abdominal pain
pain associated
cholecystokinin
cck
plasma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES04796860T
Other languages
English (en)
Inventor
Alexey L Margolin
Bhami C Shenoy
Margaret Mcgrath
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Cystic Fibrosis Foundation
Original Assignee
Eli Lilly and Co
Cystic Fibrosis Foundation Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co, Cystic Fibrosis Foundation Therapeutics Inc filed Critical Eli Lilly and Co
Application granted granted Critical
Publication of ES2421538T3 publication Critical patent/ES2421538T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4826—Trypsin (3.4.21.4) Chymotrypsin (3.4.21.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Una proteasa no pancreática seleccionada del grupo que consiste en seaprosa, pronasa y serrapeptasa parasu uso en el tratamiento de dolor abdominal asociado con insuficiencia pancreática, pancreatitis aguda,fibrosis quística o cirugía gastrointestinal posoperatoria; dolor abdominal asociado con enfermedades ytrastornos gastrointestinales seleccionados del grupo de malabsorción de proteínas (azotorrea), malabsorciónde lípidos (esteatorrea), diabetes mellitus, enfermedades ulcerosas y combinaciones de las mismas; dolorabdominal asociado con cólico biliar, colecistitis, colecistitis ascendente, colelitiasis, adicciones narcóticas,disfunción del esfínter de Oddi, vaciado gástrico retrasado o daño por quimioterapia, o dolor abdominalasociado con anorexia en un mamífero.
ES04796860T 2003-10-29 2004-10-29 Proteasas no pancreáticas para controlar la concentración de colecistocinina (CCK) en plasma y para tratar el dolor Expired - Lifetime ES2421538T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US51555203P 2003-10-29 2003-10-29
US52749003P 2003-12-05 2003-12-05
PCT/US2004/036228 WO2005042012A1 (en) 2003-10-29 2004-10-29 Non-pancreatic proteases for controlling plasma cholecystokinin (cck) concentration and for treating pain

Publications (1)

Publication Number Publication Date
ES2421538T3 true ES2421538T3 (es) 2013-09-03

Family

ID=34556008

Family Applications (1)

Application Number Title Priority Date Filing Date
ES04796860T Expired - Lifetime ES2421538T3 (es) 2003-10-29 2004-10-29 Proteasas no pancreáticas para controlar la concentración de colecistocinina (CCK) en plasma y para tratar el dolor

Country Status (9)

Country Link
US (2) US7459155B2 (es)
EP (1) EP1682168B1 (es)
JP (1) JP2007509982A (es)
KR (1) KR20060127857A (es)
AU (1) AU2004285558A1 (es)
CA (1) CA2544156C (es)
ES (1) ES2421538T3 (es)
IL (1) IL175210A (es)
WO (1) WO2005042012A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1319655B1 (it) 2000-11-15 2003-10-23 Eurand Int Microsfere di enzimi pancreatici con elevata stabilita' e relativometodo di preparazione.
DE102006008613A1 (de) * 2006-02-24 2007-08-30 Dade Behring Marburg Gmbh Stabilisierte Zubereitungen von Serin-Endopeptidasen, deren Herstellung und Verwendung
WO2008035371A2 (en) * 2006-07-11 2008-03-27 Advanced Enzyme Technologies Limited Dietary anti-bacterial compositions
SG186648A1 (en) 2007-02-20 2013-01-30 Aptalis Pharma Ltd Stable digestive enzyme compositions
US10087493B2 (en) 2008-03-07 2018-10-02 Aptalis Pharma Canada Ulc Method for detecting infectious parvovirus in pharmaceutical preparations
US8784884B2 (en) * 2009-09-17 2014-07-22 Stephen Perrett Pancreatic enzyme compositions and methods for treating pancreatitis and pancreatic insufficiency
KR20130072201A (ko) 2010-03-30 2013-07-01 피페넥스 인크. 재조합 독소 단백질의 고수준 발현
UA111726C2 (uk) 2010-10-01 2016-06-10 Апталіс Фарма Лімітед Препарат панкреліпази низької сили з кишковорозчинним покриттям
CA2835664C (en) 2011-05-12 2019-02-05 Smith & Nephew Orthopaedics Ag Wound debridement compositions containing seaprose and methods of wound treatment using same
AU2012293325B2 (en) 2011-08-08 2015-05-07 Allergan Pharmaceuticals International Limited Method for dissolution testing of solid compositions containing digestive enzymes
US20130156884A1 (en) * 2011-12-19 2013-06-20 Triarco Industries Protease enzymes for increased protein digestion rate and absorption and methods of using the same
US9962430B2 (en) 2012-02-15 2018-05-08 Chirhoclin, Inc. Methods for treating pain associated with chronic pancreatitis
CA2872530A1 (en) * 2012-05-11 2013-11-14 Smith & Nephew, Inc. Use of seaprose to remove bacterial biofilm
US11406718B2 (en) 2012-05-29 2022-08-09 Chirhoclin, Inc. Methods of detecting pancreobiliary ductal leaks
US10993996B2 (en) 2013-08-09 2021-05-04 Allergan Pharmaceuticals International Limited Digestive enzyme composition suitable for enteral administration
AU2014324897A1 (en) 2013-09-25 2016-05-19 Axcella Health Inc. Compositions and formulations for maintaining and increasing muscle mass, strength, and performance and methods of production and use thereof
WO2015193730A1 (en) 2014-06-19 2015-12-23 Aptalis Pharma Ltd. Methods for removing viral contaminants from pancreatic extracts
US11628207B2 (en) 2016-07-27 2023-04-18 Smith & Nephew, Inc. Use of thermolysin to reduce or eliminate bacterial biofilms from surfaces
EP3573622B1 (en) 2017-01-30 2023-10-18 Smith & Nephew, Inc. Synergistic combination of thermolysin and an antibacterial agent to reduce or eliminate bacterial biofilms from surfaces
US11744878B2 (en) 2020-08-19 2023-09-05 Chirhoclin, Inc. Methods for treatment of COVID-19 syndrome
WO2023286049A1 (en) 2021-07-12 2023-01-19 Zidkiyahu Simenhaus Protein containing bio-active compositions comprising cellulose microparticle carriers

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2129947A1 (en) 1971-03-23 1972-11-03 Amano Pharma Co Ltd Anti-inflammatory protease prepn - from aspergillus
JPS5692217A (en) * 1979-12-26 1981-07-25 Kowa Co Easily absorbable enzyme preparation
JPS5826822A (ja) * 1981-08-10 1983-02-17 Kaken Pharmaceut Co Ltd 慢性腎炎治療剤
JPS608225A (ja) * 1983-06-29 1985-01-17 Kowa Co 腸管吸収医薬組成物
JPS62215533A (ja) * 1986-03-17 1987-09-22 Shigemi Fujisaki 膠原病又は関節リウマチの予防治療剤
JPS61293927A (ja) * 1986-06-18 1986-12-24 Kaken Pharmaceut Co Ltd 肝臓疾患予防治療剤
JPH01132533A (ja) * 1987-11-18 1989-05-25 Toa Yakuhin Kogyo Kk 動物用薬剤
JPH01238538A (ja) * 1988-03-18 1989-09-22 Toa Yakuhin Kogyo Kk 健胃消化剤
JPH02292226A (ja) 1989-05-08 1990-12-03 Shigemi Fujisaki 障害された神経細胞賦活予防治療剤
US5514373A (en) * 1992-05-22 1996-05-07 Harris, Jr.; Roosevelt D. Topical preparation
US5628981A (en) * 1994-12-30 1997-05-13 Nano Systems L.L.C. Formulations of oral gastrointestinal diagnostic x-ray contrast agents and oral gastrointestinal therapeutic agents
WO1998036734A1 (en) * 1997-02-21 1998-08-27 Beth Israel Deaconess Medical Center Inc. A novel nutritional therapy which minimizes plasma cholecystokinin (cck) levels
JPH1149699A (ja) 1997-08-01 1999-02-23 Masao Igarashi 女性慢性下腹疼痛症候群治療剤
US6413512B1 (en) * 1998-02-13 2002-07-02 National Enzyme Company Composition and method for treating disease by increasing activated α2 macroglobulin in the blood and extravascular tissue
US6638906B1 (en) * 1999-12-13 2003-10-28 Nobex Corporation Amphiphilic polymers and polypeptide conjugates comprising same
US20010046493A1 (en) * 2000-02-24 2001-11-29 Alex Margolin Lipase-containing composition and methods of use thereof
US20040033220A1 (en) * 2000-11-02 2004-02-19 Marcus Hartmann Use of enzymes obtained from ciliates as medicaments for promoting digestion
AR032392A1 (es) * 2001-01-19 2003-11-05 Solvay Pharm Gmbh Mezcla de enzimas, preparado farmaceutico y utilizacion de dicho preparado.
US20030026794A1 (en) * 2001-07-31 2003-02-06 Howard Fein Selective enzyme treatment of skin conditions
US6713096B2 (en) * 2002-01-04 2004-03-30 Melaleuca, Inc. Dietary supplements and methods for treating pain and inflammation
US20040038874A1 (en) * 2002-08-22 2004-02-26 Osemwota Omoigui Method of treatment of persistent pain

Also Published As

Publication number Publication date
IL175210A0 (en) 2006-09-05
IL175210A (en) 2014-02-27
WO2005042012A1 (en) 2005-05-12
CA2544156A1 (en) 2005-05-12
KR20060127857A (ko) 2006-12-13
JP2007509982A (ja) 2007-04-19
AU2004285558A1 (en) 2005-05-12
US20090081184A1 (en) 2009-03-26
CA2544156C (en) 2012-07-10
US7459155B2 (en) 2008-12-02
EP1682168A1 (en) 2006-07-26
EP1682168B1 (en) 2013-05-01
US20050158299A1 (en) 2005-07-21

Similar Documents

Publication Publication Date Title
ES2421538T3 (es) Proteasas no pancreáticas para controlar la concentración de colecistocinina (CCK) en plasma y para tratar el dolor
MXPA06014462A (es) Composiciones y metodos para tratamiento de enfermedades cardiovasculares.
EA200900802A1 (ru) Способы и композиции для лечения амилоидных заболеваний
EA200600078A1 (ru) Способы и композиции для лечения амилоидных заболеваний
FR13C0052I2 (fr) Vitreolyse pharmacologique en utilisant une plasmine raccourci
EA200602092A1 (ru) Способ и композиция для лечения ринита
DE60239931D1 (de) Kombinationstherapie
DK1412357T3 (da) Beta-aminotetrahydroimidazo-(1,2-a)-pyraziner og tetrahydrotriazolo-(4,3-a)-pyraziner som dipeptidylpeptidaseinhibitorer til behandling eller forebyggelse af diabetes
NO20071018L (no) Kombinasjonsbehandling ved a anvende fusjonsproteiner omfattende GLP-1
EA201000399A1 (ru) Композиции и способы использования проостровковых пептидов и их аналогов
WO2002058730A3 (en) Compositions for treatment of ocular neovascularization
NO20062198L (no) Bradykinin B1 reseptorantagonister
ATE539745T1 (de) Zusammensetzungen zur behandlung von amyloid- assoziierten erkrankungen
NO20082345L (no) Selektive VPAC2 reseptorpeptidagonister
TR200200821T2 (tr) 5-Beta-sapojenin ve pseudosapojenin türevleri ve bunların bunama tedavisinde kullanımı.
NO20072136L (no) Substans som fremmer GH-sekresjon og anvendelse derav
ES2194784T3 (es) Procedimiento y dispositivo para el tratamiento de cuerpos despues de su fracturacion.
CL2003002293A1 (es) Compuestos derivados de indazol; su composicion farmaceutica; su uso en el tratamiento de hipertension ocular.
NO20013493D0 (no) Anvendelse av neurotrofin samt analoger derav ved behandling av gastrointestinale hypomotilitetslidelser
WO2007061924A3 (en) Methods of treating cartilage defects
DE602005020178D1 (de) 5,6,7-trihydroxyheptansäure und analoge zur behandlung von augenkrankheiten und mit hyperproliferativen und angiogenen reaktionen verbundenen krankheiten
EA200501846A1 (ru) Плазмида, кодирующая фактор роста фибробластов, для лечения ангиогенных дефектов, ассоциированных с гиперхолестеринемией или диабетом
NO20054034L (no) Fremgangsmate for behandling av hypotyroidisme.
NZ595726A (en) Compositions and methods for treatment of aortic fibrosis
EA200970588A1 (ru) Способы и композиции для лечения патологий, связанных с опосредуемым il-4 или il-13 фиброзом